

**ASX Release****Oventus 2019 Annual General Meeting  
Results**

Brisbane, Australia 22 November 2019: Oventus Medical Ltd or the Company (ASX: OVN) is pleased to announce the following results from the Annual General Meeting held on 22 November 2019.

At today's Annual General Meeting Resolutions 1 to 8 put to Shareholders were passed; and Resolution 9 was not passed. Details of the voting results are attached.



**STEPHEN DENARO  
COMPANY SECRETARY**

—ENDS—

For further information, please visit our website at [www.o2vent.com](http://www.o2vent.com) or contact the individuals outlined below.

Dr Chris Hart, Managing Director and CEO: M: +61 409 647 496 or [investors@oventus.com.au](mailto:investors@oventus.com.au)

Jane Lowe, IR Department: M: +61 411 117 774 or [jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)

**About Oventus – see more at [www.o2vent.com](http://www.o2vent.com)**

Oventus is a Brisbane-based medical device company that is commercialising a unique treatment platform for sleep apnoea and snoring. The Company has a collaborative Sleep Physician/ Dental strategy that streamlines patients' access to treatment. The Oventus lab model incorporates digital technology via intra oral scanning to achieve operational efficiencies, accuracy and ultimately patient outcomes.

Unlike other oral appliances, Oventus O2Vent devices manage the entire upper airway via a unique and patented built-in airway. O2Vent devices allow for airflow to the back of the mouth while maintaining an oral seal and stable jaw position, bypassing multiple obstructions from the nose, soft palate and tongue. The devices reduce airway collapsibility and manage mouth breathing while keeping the airway stable.

O2Vent devices are designed for any patient that is deemed appropriate for oral appliance therapy, but especially beneficial for the many people that suffer with nasal congestion, obstruction and mouth breathing. The O2Vent allows nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airway integrated in the appliance.

The ExVent™ is a valve accessory that fits into the open airway of the O2Vent Optima device, to augment traditional oral appliance therapy by stabilizing the airway. The ExVent valve contains air vents that open fully on inhalation for unobstructed airflow. The valve closes on exhalation, directing the air through the vents, creating the mild resistance or airway support required to keep the airway stable (known as PEEP, positive end expiratory pressure).

According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea<sup>1</sup>.

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnea, however many patients have difficulty tolerating CPAP<sup>2</sup>. Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnea treatment<sup>3</sup>. The O2Vent Optima and ExVent provide a discreet and comfortable alternative to CPAP for the treatment of OSA.

---

<sup>1</sup> Deloitte Access Economics. Reawakening Australia: the economic cost of sleep disorders in Australia, 2010. Canberra, Australia.

<sup>2</sup> Beecroft, et al. Oral continuous positive airway pressure for sleep apnea; effectiveness, patient preference, and adherence. Chest 124:2200–2208, 2003

<sup>3</sup> Sutherland et al. Oral appliance treatment for obstructive sleep apnea: An updated Journal of Clinical Sleep Medicine. February 2014.

**OVENTUS MEDICAL LIMITED**  
**2019 Annual General Meeting**  
**Friday, 22 November 2019**  
**Voting Results**

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth).

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of Remuneration Report	Ordinary	24,011,059 96.88%	100,561 0.41%	671,336 2.71%	0	On a Show of Hands			Carried
2 Re-election of Mr Sharad Joshi	Ordinary	59,166,902 98.87%	4,000 0.01%	673,336 1.12%	0	On a Show of Hands			Carried
3 Re-election of Ms Sue MacLeman	Ordinary	59,127,432 98.87%	4,000 0.01%	671,336 1.12%	41,470	On a Show of Hands			Carried
4 Issue of options to a Related Party Chris Hart	Ordinary	23,961,829 96.69%	122,329 0.49%	698,798 2.82%	0	On a Show of Hands			Carried
5 Issue of options to a Related Party Neil Anderson	Ordinary	23,979,300 96.76%	132,320 0.53%	671,336 2.71%	0	On a Show of Hands			Carried
6 Issue of options to a Related Party Sue MacLeman	Ordinary	23,993,600 96.81%	118,020 0.48%	671,336 2.71%	41,470	On a Show of Hands			Carried
7 Issue of options to a Related Party Sharad Joshi	Ordinary	23,993,600 96.81%	118,020 0.48%	671,336 2.71%	0	On a Show of Hands			Carried
8 Issue of options to a Related Party Mel Bridges	Ordinary	23,979,300 96.76%	132,320 0.53%	671,336 2.71%	0	On a Show of Hands			Carried
9 Approval of 10 Percent Placement Facility	Special	39,392,478 65.83%	19,780,424 33.05%	671,336 1.12%	0	41,529,758 67.74%	19,780,424 32.26%	0	Not Carried

\* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.